A Comparison of p53-induced Genes Activation in Patients With and Without Acute Myocardial Infarction
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
The purpose of this study is to compare p53-induced genes activation as possible markers differentiating between patients presenting with acute myocardial infarction and controls.
Condition | Intervention |
---|---|
Acute Myocardial Infarction |
Other: Blood test |
Study Type: | Observational |
Study Design: | Observational Model: Case Control Time Perspective: Prospective |
Official Title: | A Comparison of p53-induced Genes Activation as Possible Markers Differentiating Between Patients Presenting With Acute Myocardial Infarction and Controls |
- Expression of P53 induced genes in patients with and without acute myocardial infarction [ Time Frame: Up to 4 hours following recruitment ] [ Designated as safety issue: No ]
- Correlation between P53 associated gene expression with troponin level [ Time Frame: After 5 days from recruitment ] [ Designated as safety issue: No ]
Estimated Enrollment: | 125 |
Study Start Date: | November 2010 |
Groups/Cohorts | Assigned Interventions |
---|---|
acute MI group
Patients presenting with acute ST elevation myocardial infarction, admitted to the intensive cardiac care unit and that are planned for emergency primary PCI
|
Other: Blood test
Blood test
|
Controls
Patients undergoing a non-invasive evaluation of possible myocardial ischemia.
|
Other: Blood test
Blood test
|
Detailed Description:
The diagnosis of acute myocardial infarction is based on the rise of bio-markers for cardiac necrosis such as troponin. While troponin measurement is highly sensitive for myocardial necrosis it has several limitations that influence its clinical use. First, since the troponin test is reliable only after 4-6 hours from symptoms onset, it has only limited value in the assessment of patients presenting earlier. Second, several clinical situations, most commonly renal dysfunction, are associated with increased troponin level and therefore may decrease the specificity of the test. Third, since troponin rise indicates myocardial infarction it is not useful in the common situations where there is myocardial ischemia without necrosis.
The P53 is a tumor suppressing gene activated in different stressful situations including hypoxia. This activation is associated with accelerated transcription (up to 30-50 folds from baseline) of different genes that are involved in apoptosis, DNA repair and in stopping the cell cycle. A study on pregnant women demonstrated high levels of fetal mRNA of these genes in maternal circulation. This gene expression correlated with other signs of fetal stress associated with hypoxia. Myocardial ischemia is another stressful event associated with tissue hypoxia. Nevertheless, the association of this gene expression with myocardial ischemia has not been investigated yet.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Aacute MI group- Patients with acute ST elevation MI planned for emergency primary PCI
Controls: Patients undergoing non-invasive evaluation of possible myocardial ischemia
Inclusion Criteria:
Acute MI group:
Patient presenting with chest pain lasting for at leasY 1 hour and no more than 6 hours accompanied by 1 of the following ECG criteria:
- ST segment elevation of anterior or inferior wall (at least 2 consecutive leads)
- New LBBB
Controls:
- Patients undergoing non-invasive evaluation of possible myocardial ischemia
Exclusion Criteria:
- Chronic lung disease requiring chronic treatment
- Any malignancy in the 5 year prior to enrollment
Contact: David Pereg, MD | 972-9-7472587 | davidpe@post.tau.ac.il |
Contact: Morris Mosseri, MD | 972-9-7458179 | morris.mosseri@clalit.org.il |
Israel | |
Meir Medical Center | Recruiting |
Kfar Saba, Israel | |
Principal Investigator: David Pereg, MD | |
Sub-Investigator: Osnat Ashur-Fabian, Phd | |
Sub-Investigator: Morris Mosseri, MD |
Publications:
Responsible Party: | Meir Medical Center |
ClinicalTrials.gov Identifier: | NCT01191879 History of Changes |
Other Study ID Numbers: | MRNA-MI-1 |
Study First Received: | August 8, 2010 |
Last Updated: | March 16, 2012 |
Health Authority: | Israel: Ethics Commission |
Additional relevant MeSH terms:
Infarction Myocardial Infarction Ischemia Pathologic Processes Necrosis |
Myocardial Ischemia Heart Diseases Cardiovascular Diseases Vascular Diseases |
ClinicalTrials.gov processed this record on October 17, 2012